Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab
Authors' conclusion
Our longitudinal investigation suggests that BMI increase may not lead to changes in DAS28-esr in patients receiving infliximab, despite the weight-adapted dose. Yet, there may be a decrease in erosions with increasing weight non-limited to obese patients.
Study context
- Population
- Infliximab users with rheumatoid arthritis (RA) in the Swiss Clinical Quality Management in Rheumatic Diseases registry (1997–2020)cohort 1: 412
- Exposure
- Association of body mass index (BMI) with changes in DAS28-ESR and Rau score in infliximab-treated RA
- Outcome
- Changes in mean DAS28-ESR (cohort 1) and mean Rau scores (cohort 2) with BMI
Methodological detailsregistry-based (SCQM, 1997-2020), generalised estimation equations, stratified by BMI categories
- Registry-based (SCQM, 1997-2020)
- Generalised estimation equations
- Stratified by BMI categories
Main finding
As reported in the abstract
Change in mean DAS28-ESR per BMI increase (cohort 1)
Adjusted coefficient (95% CI −0.02 to 0.02); no change, overall or in BMI categories
0.00
Observational data: associations, not effects.
Further findings
Change in mean Rau score per BMI unit increase (cohort 2)
- Adjusted coefficient (95% CI −1.92 to −0.19); significant decrease
- −1.05
- Results statistically non-significant across BMI categories
Original publication
Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab. RMD Open. Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →